Versiti, a national leader in blood health innovation, today announced the acquisition of Missouri-based Ethical and Independent Review Services (E&I). Further expanding Versiti’s clinical trial services and expertise, E&I provides independent institutional review board (IRB) services to ensure thorough, timely reviews of research involving human subjects.

“Versiti and E&I share a mission-focused approach to advancing medical science and patient care through clinical trials,” said Versiti President and CEO Chris Miskel. “Joining forces with E&I allows us to expand our services to additional research areas with an industry-leading, best practice approach.”

An AAHRPP-accredited independent IRB, E&I provides in-depth regulatory expertise to support the development of ethical and quality research designs for social and behavioral research as well as the biopharmaceutical and medical device industries.

Click here to read the full article.